In the version of this article originally published online and in print, nivolumab was incorrectly stated as targeting programmed cell death 1 ligand 1 (PD-L1), rather than programmed cell death protein 1 (PD-1). This error has now been corrected in the online HTML and PDF versions of the article.
Additional information
The online version of the original article can be found at 10.1038/nrclinonc.2015.178
Rights and permissions
About this article
Cite this article
Thoma, C. Correction: CheckMate for advanced-stage ccRCC? Nivolumab and cabozantinib aMETEORate poor survival. Nat Rev Clin Oncol 12, 742 (2015). https://doi.org/10.1038/nrclinonc.2015.207
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2015.207
